Navigation Links
OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
Date:5/27/2009

BOTHELL, WA and VANCOUVER, May 27 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company will hold a live webcast and conference call of presentations made at an OncoGenex hosted reception during the 2009 American Society of Clinical Oncology Annual Meeting (ASCO) on Saturday, May 30, 2009. The webcast will begin at 7:10 p.m. EDT.

During the reception, OncoGenex management and guest speakers will provide a comprehensive review of the final results of a randomized Phase 2 trial presented during an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, as well as discuss the treatment landscape and the relevance of clinical trial endpoints for prostate cancer.

    Guest speakers include:

    Dr. Kim Chi, OGX-011 Principal Investigator, BC Cancer Agency
    Dr. Oliver Sartor, Medical Oncologist, Tulane Medical School
    Dr. Tomasz Beer, Medical Oncologist, Oregon Health & Science University
    Dr. Brent Blumenstein, Independent Statistician, Trial Architecture
    Consulting
    Dr. Martin Gleave, Distinguished Professor, Department of Urologic
    Sciences, University of British Columbia and Chief Scientific Officer,
    OncoGenex Pharmaceuticals, Inc.

To access the webcast, log on to the Investor Relations page of the OncoGenex Web site at www.oncogenex.com. Alternatively, you may access the live conference call by dialing 877-627-6544 (U.S. & Canada) or 719-325-4857 (International). A webcast replay will be available approximately two hours after the call and will be archived at www.oncogenex.com.

About OncoGenex Pharmaceuticals

OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed enrollment in a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information is available at www.oncogenex.com.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that its new website has gone live. On Thursday, ... mobile-friendly. Visit the new site: www.diplomat.is ... ... ... "The goal was to reimagine the website and create ...
(Date:2/6/2016)... ... February 06, 2016 , ... The Center for Excellence in Education (CEE) will ... teachers on Wednesday February 10, 2016. This Bite of Science session, hosted by ... located at 1500 Remount Road in Front Royal, VA from 5:00 p.m. to 8:00 ...
(Date:2/5/2016)... MANASSAS, Va. , Feb. 5, 2016 ... organization, is poised to assist the medical and life ... concerns around Zika Virus infection.   CDC ... --> Zika virus is a single-stranded ... also includes the West Nile, Dengue and Chikungunya Viruses. ...
(Date:2/5/2016)... , Feb. 5, 2016 On Thursday, February ... information source for community, health and disaster services, and ... will integrate to enhance care coordination and service delivery ... services they need and to better connect service providers ... San Diego has handled ...
Breaking Biology Technology:
(Date:2/2/2016)... 2016 Checkpoint Inhibitors for Cancer – ... Are you interested in the future of cancer ... inhibitors. Visiongain,s report gives those predictions to 2026 ... level. Avoid falling behind in data or ... revenues those emerging cancer therapies can achieve. There ...
(Date:2/2/2016)... , Feb. 2, 2016   Parabon NanoLabs ... the U.S. Army Research Office and the Defense ... and sensitivity of the company,s Snapshot Kinship ... Mission and, more generally, defense-related DNA forensics.  Although ... capabilities (predicting appearance and ancestry from DNA evidence), ...
(Date:2/1/2016)... 2016 Rising sales of consumer ... touchfree intuitive gesture control market size ... of consumer electronics coupled with new technological advancements to ... size through 2020   --> ... technological advancements to drive global touchfree intuitive gesture control ...
Breaking Biology News(10 mins):